He warned that obesity is driving a surge in serious illnesses, including Type 2 diabetes and heart disease, placing growing pressure on families, communities and the health system.

People who quit taking popular GLP-1 drugs such as Ozempic might their jeopardize heart health, according to a new study.

Research finds that even short gaps in treatment with a GLP-1 can drive up risks of heart attack, stroke and death in patients with Type 2 diabetes.

Clinical and payer strategies should treat GLP‑1 therapy as chronic for high-risk patients, addressing tolerability and cost ...

A study following more than 5,000 participants for 12 years found that straightforward clinical measurements can help identify sarcopenic obesity without relying on complex imaging methods such as MRI ...

Nearly 1 in 5 teens in the United States is obese, putting their long-term health at serious risk. Obesity in adolescence ...

Drug executives say only their GLP-1 drugs are safe for treating obesity and diabetes as they wage a yearlong campaign to stop independent labs from producing cheaper versions. Former Novo Nordisk CEO ...

Age-adjusted rates of cardiovascular disease (CVD) mortality tripled from 3.4 to 10.34 per 100,000 people between 1999 and 2023 among US adults with obesity, with higher rates observed in men, older ...

(Andrey Sayfutdinov/iStock/Getty Images Plus) A worrying health pattern for some of the Gen X and Millennial crowd has been ...

A new study published in the Journal of American Medical Association showed that the chance of mortality is greater for ...